Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The US District Court in Delaware has ruled in favor of Cephalon related to its patent infringement lawsuit against Watson Pharmaceuticals.
Subscribe to our email newsletter
The court has said that Cephalon‘s US Patent number 6,264,981is valid and also found that Watson Pharma’s proposed generic version of Fentora (fentanyl buccal tablet) infringes that patent.
The Court also denied Watson Pharma‘s motion to vacate a previously entered injunction preventing Watson from marketing its product.
Cephalon General Counsel executive vice president Jerry Pappert said they are pleased with the court’s ruling upholding the validity of their patent, as well as its finding that Watson’s product infringes that patent.